Patient Presents With Enlarged Axillary Lymph Nodes

Poll

A 22-year-old man presents with enlarged axillary lymph nodes. What is your diagnosis?

A 22-year-old man presents with enlarged axillary lymph nodes.

What is your diagnosis?

A. Castleman disease
B. Inflammatory pseudotumor
C. Hodgkin lymphoma
D. Acute lymphocytic leukemia
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Related Content
The rate of 35% reduction in spleen volume or higher was higher pelabresib/ruxolitinib vs ruxolitinib alone in the MANIFEST-2 trial.

Pelabresib Combo Improves Efficacy Vs Ruxolitinib Alone in Myelofibrosis

Paige Britt
December 9th 2025
Article

The rate of 35% reduction in spleen volume or higher was higher pelabresib/ruxolitinib vs ruxolitinib alone in the MANIFEST-2 trial.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

More than half of evaluable patients in the phase 1/2 NEXICART-2 trial experienced organ responses following treatment with NXC-201.

NXC-201 Yields Rapid Responses in Small R/R AL Amyloidosis Cohort

Russ Conroy
December 8th 2025
Article

More than half of evaluable patients in the phase 1/2 NEXICART-2 trial experienced organ responses following treatment with NXC-201.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

Survival Similar With MMUD Grafts in GVHD Care Regardless of Match Level

Roman Fabbricatore
December 6th 2025
Article

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.

The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies

Ram Prakash Thirugnanasambandam, MBBS;Ariana Bauer, MD;Christopher D’Angelo, MD
December 3rd 2025
Article

AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.